Manufacturing built around your process.

1Pharmaceutical manufacturing software is broader than MES.

A facility should be able to prove what happened to a batch, why it was allowed to proceed and which evidence supported release, without rebuilding the story from paper, spreadsheets and disconnected applications.

A manufacturing execution system controls work on the shop floor. Pharmaceutical manufacturing also depends on records that begin before execution and finish after it: supplier approval, receipt and sampling, specifications, instrument data, calibration, training, deviations, CAPA, stability, complaints and disposition. FDA identifies 21 CFR parts 210 and 211 among the core CGMP regulations for drugs, and its CGMP regulations resource shows the breadth: facilities, equipment, components, production, packaging, laboratory controls, records and distribution all contribute to control.

Seal connects materials, batch execution, equipment state, testing, quality events, labels and disposition around shared products and batches. Production, QC, engineering, warehouse and quality each work in their own controlled view while contributing to the same manufacturing record. The MES blueprint explains how approved recipes become guided execution; this paper explains how execution, laboratory, quality, inventory, equipment and release operate as one system.

1.1Why teams choose Seal for pharmaceutical manufacturing

Build receipt, execution, testing, quality and disposition on the same platform, with the links between products, batches and results defined in Seal’s ontology. Your team can ask Neil to investigate an exception across that history and build a proposed change to the workflow. Test and approve the next version, then use it for new work while earlier batches retain their original instructions and evidence. The investigation becomes a way to improve the operation, with less time spent assembling the batch story.

2Decide which system owns each record.

An application architecture can look complete while the operation remains fragmented. The decisive design work is deciding which system owns each object and decision.

Interfaces must carry identity and state, not copies of documents. A receipt needs the supplier and internal lot, status, quantity and sampling state; a process value needs its batch, step, tag, timestamp, units and quality status; a result needs its sample, method, specification and reviewer. Seal records acknowledgement and retries at each boundary, so that a correction, outage or late result is reconciled against the existing record rather than leaving two versions of it.

The same discipline applies to shared definitions. Products, materials, specifications, methods, equipment classes, suppliers and label content are defined once and reused, with approved definitions kept separate from live records. A new process or specification version does not silently change a batch already in progress; change control identifies the dependent records, training, inventory, open batches, labels and markets before the new state takes effect.

Electronic signatures and audit trails are necessary, but they do not compensate for weak process design. Electronic-record controls operate alongside the underlying predicate rules,¹ and FDA’s data-integrity guidance addresses completeness, consistency and accuracy across the data lifecycle.² In Seal, attributable actions, timestamps, versions, reasons for change, signatures and retention apply at the record level, interface data keeps its source, and corrections never overwrite history.

3Material control begins at receipt.

Incoming materials, components, containers, closures and printed items enter with their supplier, manufacturer lot, quantity, condition, certificates, storage requirements and receiving observations. Seal creates the internal lot and its initial status. Sampling uses the approved plan and identifies the physical containers selected, and results, identity checks, supplier documentation and quality review resolve the disposition. Quarantine, approved, restricted, rejected and expired states control which operations may consume the lot.³

Warehouse transactions preserve container identity, quantity, location, status and custody. Dispensing records the actual source containers, balances, quantities, tolerances, operator, verifier and destination batch. A supplier finding can then trace forward to every dispensed quantity and affected batch, and a batch investigation can trace back to the original receipt.

4Execution and equipment state gate the batch.

The master manufacturing record is an executable definition, not a formatted document on a screen. It contains prerequisites, sequence, parameters, calculations, material and equipment rules, in-process checks, holds, signatures and authorised exception paths. When an order is created, Seal resolves the effective product, process, batch size and market. Operators see only the work that is currently actionable, barcode checks verify the physical object against the instruction, and values are entered, calculated or acquired from equipment with their source retained.

Required data cannot be deferred by leaving a blank line for later. Corrections preserve the original value, reason, author and time; out-of-range entries follow their configured response; and a deviation can begin at the batch step with materials, equipment, people and quantities already linked. The Electronic Batch Records blueprint covers authoring, exceptions, review and paper migration in detail.

Equipment state controls execution in the same way. Each asset carries its qualification, calibration, maintenance, cleaning, location and product-contact history. An overdue calibration, open critical maintenance order, failed cleaning verification or incompatible prior product prevents normal use and invokes the approved exception path. If an asset is later found unacceptable, impact assessment starts with the batches, tests and measurements performed since its last known acceptable state.

5Testing and quality events start from the affected object.

QC is not a queue beside manufacturing. A sample exists because an incoming material, in-process stage, cleaning verification, environmental location, stability pull or finished batch needs a decision. Seal creates it with its source, specification, methods and decision attached, and keeps custody, standards, instruments, raw data, calculations and review connected. CDS and instruments can remain authoritative for acquisition while Seal receives controlled results and source references. FDA’s laboratory controls Q&A stresses that failing, passing, suspect and erroneous data all belong in the CGMP record.

An approved in-process result can release the waiting manufacturing step. A failure can hold the affected batch, material or equipment and open OOS or deviation work, and finished-product results populate disposition and the certificate of analysis from the same approved data.

A deviation should not begin as an empty form. Seal opens it from the material, step, equipment, sample, result or supplier where the event occurred, capturing containment, affected population and severity while the context is available. Investigation, product impact, CAPA, effectiveness and change control stay connected to the original event, so recurrence can be analysed by product, process version, material lot, equipment or failure mode. Complaints work the same way: a complaint against a distributed lot traces into its manufacturing, testing, deviations and suppliers.

6Packaging, labels and release draw on the same evidence.

Packaging has its own components, equipment, line clearance, inspection, coding, yields, rejects and reconciliation, and Seal treats bulk product, packaged lots and labels as explicit genealogy states. Approved label content is governed separately from variable data such as lot, expiry and identifiers, which render from controlled records. Issuance, use, rejects, destruction and reprints reconcile against the packaging order, and a change to approved text identifies the affected products, markets, inventory and unreleased batches.

Release begins when the batch begins. Genealogy, execution, equipment, results, yields, labels and quality events mature into a disposition record as work completes. QA reviews completed stages and exceptions concurrently, with the full record available. At disposition, Seal resolves the evidence required for the effective product, site and market, and the approval updates the batch, containers, inventory eligibility and certificate of analysis from one decision. Rejected, restricted and reprocessing states remain explicit and cannot be mistaken for release. Batch production records must document that each significant step was accomplished.⁴ Their review must thoroughly investigate any unexplained discrepancy, with a written record of the conclusions.⁵ The software therefore has to preserve the evidence rather than produce a neat PDF.

7Extend across modalities from one receipt-to-release thread.

Oral solid dose, sterile injectables, APIs, biologics and combination products do not share a process, but they can share control principles: approved definitions, material identity, guided execution, equipment eligibility, sample-to-decision traceability, exception handling and accountable disposition. Modality blueprints extend that foundation. Aseptic manufacturing adds contamination control, interventions and process simulations; API manufacturing adds non-linear transformations, recovered materials and reprocessing; biologics manufacturing adds cell-bank lineage, seed trains and viral safety. Adding a dosage form should extend controlled patterns, not start a new quality system.

Do not begin by configuring every document and product. Select one representative product and prove the full thread:

1. receive, sample, test and release a material, then dispense it to an approved batch order;
2. execute the master record with equipment and training gates;
3. create and test in-process and finished-product samples;
4. exercise a correction, deviation, failed result and equipment exception;
5. package, reconcile and generate controlled labels;
6. review by exception and disposition the batch;
7. trace backward from the finished product and forward from a source lot.

That thread exposes master-data gaps, unclear ownership, interface failure modes, permissions, validation scope and training needs early. Once the operation can execute and explain one complete batch, including its failure paths, the approved patterns can scale across products, suites and sites.